## 1

## 2 Title

3

Quantitative Mass Spectrometry Analysis of Cerebrospinal Fluid Protein Biomarkers in
 Alzheimer's Disease

- 67 Authors
- 8

9 Caroline M. Watson<sup>1</sup>, Eric B. Dammer<sup>1</sup>, Lingyan Ping<sup>1</sup>, Duc M. Duong<sup>2</sup>, Erica Modeste<sup>1</sup>, E.
10 Kathleen Carter<sup>2</sup>, Erik C. B. Johnson<sup>1</sup>, Allan I. Levey<sup>1\*</sup>, James J. Lah<sup>1\*</sup>, Blaine R. Roberts<sup>1,2</sup>, and
11 Nicholas T. Seyfried<sup>1,2\*</sup>

- 12
- 13

## 14 Affiliations

- 15 1. Department of Neurology, Emory University School of Medicine
- 16 2. Department of Biochemistry, Emory University School of Medicine
- 17 corresponding author(s): Nicholas T. Seyfried, PhD (<u>nseyfri@emory.edu</u>); James J. Lah, MD,
- 18 PhD. (jlah@emory.edu); Allan I Levey, MD, PhD. (alevey@emory.edu)

19

## 20 Abstract

21

22 Alzheimer's disease (AD) is the most common form of dementia, with cerebrospinal fluid (CSF) 23  $\beta$ -amyloid (A $\beta$ ), total Tau, and phosphorylated Tau providing the most sensitive and specific 24 biomarkers for diagnosis. However, these diagnostic biomarkers do not reflect the complex 25 changes in AD brain beyond amyloid (A) and Tau (T) pathologies. Here, we report a selected 26 reaction monitoring mass spectrometry (SRM-MS) method with isotopically labeled standards 27 for relative protein quantification in CSF. Biomarker positive (AT+) and negative (AT-) CSF pools 28 were used as quality controls (QCs) to assess assay precision. We detected 62 peptides (51 29 proteins) with an average CV of ~13% across 30 QCs and 133 controls (cognitively normal, AT), 30 127 asymptomatic (cognitively normal, AT+) and 130 symptomatic AD (cognitively impaired, 31 AT+). Proteins that could distinguish AT+ from AT- individuals included SMOC1, GDA, 14-3-3 32 proteins, and those involved in glycolysis. Proteins that could distinguish cognitive impairment 33 were mainly neuronal proteins (VGF, NPTX2, NPTXR, and SCG2). This demonstrates the utility 34 of SRM-MS to quantify CSF protein biomarkers across stages of AD.

35

## 36 Background & Summary

37

38 Alzheimer's disease (AD) affects more than 45 million people worldwide, making it the most 39 common neurodegenerative disease<sup>1</sup> (https://www.alz.org/media/Documents/alzheimers-40 facts-and-figures-2019-r.pdf; https://www.alzint.org/u/WorldAlzheimerReport2015.pdf). AD 41 biomarker research has predominately focused on  $\beta$ -amyloid (A $\beta$ ) and Tau, as these proteins reflect pathological A $\beta$  plaques and tau neurofibrillary tangles (NFT), respectively, in AD<sup>2,3</sup>. 42 43 Although AB and Tau are the most sensitive and specific CSF biomarkers for diagnosis<sup>4,5</sup> these two proteins do not reflect the heterogenous and complex changes in AD brain<sup>6,7</sup>. 44 45 Furthermore, failed clinical trials of A $\beta$ -based therapeutic approaches highlight the complexity 46 of AD and the need for additional biomarkers to fully illustrate pathophysiology for 47 advancements in diagnostic profiling, disease monitoring, and treatments<sup>1,7</sup> 48 (https://www.alz.org/media/Documents/alzheimers-facts-and-figures-2019-r.pdf;

- 49 https://www.alzint.org/u/WorldAlzheimerReport2015.pdf).
- 50

51 Considering the diagnostic challenges related to the overlapping pathologies of 52 neurodegenerative diseases, AD biomarkers that represent diverse pathophysiological

changes could facilitate an early diagnosis, predict disease progression, and enhance the understanding of neuropathological changes in AD<sup>1</sup>. AD has a characteristic pre-clinical or asymptomatic period (AsymAD) where individuals have AD neuropathology in the absence of clinical cognitive decline<sup>3,8,9</sup>. Thus, biomarkers for the prodromal phase of AD that can begin changing years or decades before signs of cognitive impairment, would be valuable for disease intervention, clinical trial stratification, and monitoring drug efficacy.

59

Proteins are the proximate mediators of disease, integrating the effects of genetic, epigenetic, 60 and environmental factors<sup>7,10</sup>. Network proteomic analysis has emerged as a valuable tool for 61 organizing complex unbiased proteomic data into groups or "modules" of co-expressed 62 proteins that reflect various biological functions, i.e., systems biology <sup>11-14</sup>. The direct proximity 63 64 of CSF to the brain presents a strong rationale to integrate the brain and CSF proteomes to increase the pathophysiological diversity among biofluid biomarkers of AD<sup>5,15</sup>. We recently 65 66 integrated a human AD brain proteomic network with a CSF proteome differential expression 67 analysis and revealed approximately 70% of the CSF proteome overlapped with the brain proteome<sup>16</sup>. Nearly 300 CSF proteins were identified as significantly altered between control 68 69 and AD samples, representing predominately neuronal, glial, vasculature and metabolic 70 pathways, creating an excellent list of candidates for further quantification and validation. 71

72 Here, we developed a high-throughput targeted selected reaction monitoring-based mass 73 spectrometry (SRM-MS) assay<sup>17</sup> to quantify and validate reliably detected CSF proteins in healthy individuals and individuals with asymptomatic or symptomatic AD for staging AD 74 75 progression. We evaluated 200+ tryptic peptides that were selected using a data-driven 76 approach from the integrated brain-CSF proteome network analysis. We selected peptides 77 with differential abundance in AD CSF observed in >50 percent of case samples by discovery 78 proteomics<sup>16</sup> for synthesis as crude heavy standards. We used two pooled CSF reference standards to determine which peptides were reliably detected in CSF matrix. We reproducibly 79 80 detected and reliably quantified 62 tryptic peptides from 51 proteins in 390 clinical samples 81 and 30 pooled reference standards. Furthermore, using a combination of differential 82 expression and receiver operating curve (ROC) analyses we found CSF proteins that can best 83 discriminate stages of AD progression. Collectively, these data highlight the utility of a high throughput SRM-MS approach to quantify biomarkers associated with AD that ultimately hold 84 85 promise for monitoring disease progression, stratifying patients for clinical trials, and 86 measuring therapeutic response. Future studies will be necessary to assess the diagnostic and 87 predictive utility of our CSF peptide SRM panel against gold-standard CSF (amyloid, tau and 88 pTau) and imaging AD biomarkers in larger prospective patient cohorts.

89 90

#### 91 Methods

92

## 93 Reagents and materials

94 Heavy labeled peptides (Thermo PEPotec SRM Peptide Libraries; Grade 2; crude as 95 synthesized), trypsin, mass spectrometry grade, trifluoroacetic acid (TFA), foil heat seals (AB-96 0757), and low-profile square storage plates (AB-1127) were purchased from ThermoFisher 97 Scientific (Waltham, MA). Lysyl endopeptidase (Lys-C), mass spectrometry grade was bought 98 from Wako (Japan); sodium deoxycholate, CAA (chloroacetamide), TCEP (tris-2(-carboxyethyl)-99 phosphine), and triethylammonium hydrogen carbonate buffer (TEAB) (1 M, pH 8.5) were 100 obtained from Sigma (St. Louis, MO). Formic acid (FA), 0.1% FA in acetonitrile, 0.1% FA in 101 water, methanol, and sample preparation V-bottom plates (Greiner Bio-One 96-well 102 Polypropylene Microplates; 651261) are from Fisher Scientific (Pittsburgh, PA). Oasis PRIME 103 HLB 96-well, 30mg sorbent per well, solid phase extraction (SPE) cleanup plates were from 104 Waters Corporation (Milford, MA).

105

#### 106

#### 107 Pooled CSF as quality controls

108 Two pools of CSF were generated based on A $\beta$ (1-42), total Tau, and pTau181 levels to create 109 AD-positive (AT+) and AD-negative (AT-) quality control standards. Each pool consisted of 110 approximately 50 mL of CSF by combining equal volumes of CSF selected from well 111 characterized samples (~45 unique individuals per pool) from the Emory Goizueta Alzheimer's 112 Disease Research Center (GADRC) and Emory Healthy Brain Study (EHBS). All research 113 participants provided informed consent under protocols approved by the Institutional Review 114 Board (IRB) at Emory University. CSF was collected by lumbar puncture and banked according 115 to 2014 ADC/NIA best practices guidelines (https://www.alz.washington.edu/Biospecimen 116 TaskForce.html). AD biomarker status for individual cases was determined on the Roche Elecsys<sup>®</sup> immunoassay platform<sup>18-20</sup>; the average CSF biomarker value is reported in 117 118 parentheses. The control CSF pool (AT-) was comprised of cases with relatively high levels of 119  $A\beta(1-42)$  (1457.3 pg/mL) and low total Tau (172.0 pg/mL) and pTau181 (15.1 pg/mL). In 120 contrast, the AD pool (AT+) was comprised of cases with low levels of A $\beta$ (1-42) (482.6 pg/mL) 121 and high total Tau (341.3 pg/mL) and pTau181 (33.1 pg/mL). The quality control (QC) pools 122 were processed and analyzed identically to the CSF clinical samples reported.

#### 123

#### 124 Clinical characteristics of the cohort

125 Human cerebrospinal fluid (CSF) samples from 390 individuals including 133 healthy controls, 126 130 patients with symptomatic AD, and 127 asymptomatic AD patients (cognitively normal but 127 AD biomarker positive) were obtained from Emory's GADRC and EHBS (Fig. 1 and Table 1). All 128 symptomatic individuals were diagnosed by expert clinicians in the ADRC and Emory Cognitive 129 Neurology Program, who are subspecialty trained in Cognitive and Behavioral Neurology, 130 following extensive clinical evaluations including detailed cognitive testing, neuroimaging, and 131 laboratory studies. CSF samples were selected to balance for age and sex (Table 1). For 132 biomarker measurements, CSF samples from all individuals were assayed for A $\beta$ (1-42), total Tau, and pTau using the Roche Diagnostics Elecsys<sup>®</sup> immunoassay platform<sup>18-20</sup>. The cohort 133 characteristics are summarized in Fig. 1 and Table 1. Compared to our previous CSF 134 135 studies<sup>14,16,21</sup>, there is minimal overlap with 329 of the 390 CSF samples (~84%) unique to this 136 study. Samples were stratified into controls, AsymAD, and AD based on Tau and Amyloid 137 biomarkers status and cognitive score from the Montreal Cognitive Assessment (MoCA). All 138 case metadata including disease state, age, sex, race, apolipoprotein (ApoE) genotype, MoCA 139 scores, and biomarkers measurements were deposited on Synapse<sup>22</sup>.

140

#### 141 Peptide selection and selected reaction monitoring assay

We harnessed both deep discovery and single-shot tandem mass tag (ssTMT) peptide data 142 from CSF proteomics<sup>14,16</sup>. Here, we prioritized peptides for SRM validation that i) had one or 143 144 more spectral match, ii) were differentially abundant (AD versus control) iii) or that mapped 145 to proteins within brain-based biological panels that differed in AD<sup>16</sup>. Ultimately, we 146 nominated 200+ peptides for synthesis as crude heavy standards. The heavy peptides contained isotopically labeled C-terminal lysine or arginine residues (<sup>13</sup>C, <sup>15</sup>N) for each tryptic 147 148 peptide. Based on the crude heavy peptide signal, the peptides were pooled to achieve total 149 area signals  $\geq 1 \times 10^5$  in CSF matrix. The transition lists were created in Skyline-daily software (version 21.2.1.455)<sup>23,24</sup>. An in-house spectral library was created in Skyline based on tandem 150 151 mass spectra from CSF samples. Skyline parameters were specified as: trypsin enzyme, Swiss-152 Prot background proteome, and carbamidomethylation of cysteine residues (+57.02146 Da) 153 as fixed modifications. Isotope modifications included:  ${}^{13}C_{6}{}^{15}N_4$  (C-term R) and  ${}^{13}C_{6}{}^{15}N_2$  (C-term 154 K). The top ten fragment ions that matched the criteria (precursor charges: 2; ion charges 1, 155 2; ion types: y, b) were selected for scrutiny. The top 5-7 transitions per heavy precursor were 156 selected by manual inspection of the data in Skyline and scheduled transition lists were

created for collision energy optimization. Collision energies were optimized for each transition; the collision energy was ramped around the predicted value in 3 steps on both sides, in 2V increments<sup>25</sup>. The selected transitions were tested in real matrix spiked with the heavy peptide mixtures. The three best transitions per precursor were selected by manual inspection of the data in Skyline and one scheduled transition list was created for the final assays. A list of transitions used in this study is deposited on Synapse<sup>22</sup>.

163

#### 164 **Preparation of CSF for mass spectrometric analysis**

165 All CSF samples were blinded and randomized. Each CSF sample was thawed and aliguoted 166 into sample preparation V-bottom plates that also included quality controls. Each sample and 167 quality control were processed independently in parallel. Crude CSF (50 μL) was reduced, 168 alkylated, and denatured with tris-2(-carboxyethyl)-phosphine (5 mM), chloroacetamide (40 169 mM), and sodium deoxycholate (1%) in triethylammonium bicarbonate buffer (100 mM) in a 170 final volume of 150 µL. Sample plates were heated at 95°C for 10 min, followed by a 10-min 171 cool down at room temperature while shaking on an orbital shaker (300 rpm)<sup>26</sup>. CSF proteins 172 were digested with Lys-C (Wako; 0.5  $\mu$ g; 1:100 enzyme to CSF volume) and trypsin (Pierce; 5 173  $\mu$ g; 1:10 enzyme to CSF volume) overnight in a 37°C oven. After digestion, heavy labeled 174 standards for relative quantification (15 µL per 50 µL CSF) were added to the peptide solutions 175 followed by acidification to a final concentration of 0.1% TFA and 1% FA (pH  $\leq$  2). Sample plates 176 were placed on an orbital shaker (300 rpm) for at least 10 minutes to ensure proper mixing. Plates were centrifuged (4680 rpm) for 30 minutes to pellet the precipitated surfactant. 177 178 Peptides were desalted with Oasis PRIME HLB 96-well, 30mg sorbent per well, solid phase 179 extraction (SPE) cleanup plates from Waters Corporation (Milford, MA) using a positive 180 pressure system. Each SPE well was conditioned (500 µL methanol) and equilibrated twice 181 (500 µL 0.1% TFA) before 500 µL 0.1% TFA and supernatant were added. Each well was washed 182 twice (500  $\mu$ L 0.1% TFA) and eluted twice (100  $\mu$ L 50% acetonitrile/0.1% formic acid). All 183 eluates were dried under centrifugal vacuum and reconstituted in 50 µL mobile phase A (0.1% 184 FA in water) containing Promega 6 × 5 LC-MS/MS Peptide Reference Mix (50 fmol/µL; Promega 185 V7491).

186

#### 187 Liquid chromatography-tandem mass spectrometry (LC-MS/MS)

188 Peptides were analyzed using a TSQ Altis Triple Quadrupole mass spectrometer (Thermo 189 Fisher Scientific). Each sample was injected (20 µL) using a 1290 Infinity II system (Agilent) and 190 separated on an AdvanceBio Peptide Map Guard column (2.1x5mm, 2.7 μm, Agilent) 191 connected to AdvanceBio Peptide Mapping analytical column (2.1x150mm, 2.7 μm, Agilent). 192 Sample elution was performed over a 14-min gradient using mobile phase A (MPA; 0.1% FA in 193 water) and mobile phase B (MPB; 0.1% FA in acetonitrile) with flow rate at 0.4 mL/min. The 194 gradient was from 2% to 24% MPB over 12.1 minutes, then from 24% to 80% over 0.2 min and 195 held at 80% B for 0.7 min. The mass spectrometer was set to acquire data in positive-ion mode 196 using selected reaction monitoring (SRM) acquisition. Positive ion spray voltage was set to 197 3500 V for the Heated ESI source. The ion transfer tube and vaporizer temperatures were set 198 to 325°C and 375°C, respectively. SRM transitions were acquired at Q1 resolution 0.7 FWHM, 199 Q2 resolution 1.2 FWHM, CID gas 1.5 mTorr, 0.8 s cycle time.

200

#### 201 Data analysis

Raw files from Altis TSQ were uploaded to Skyline-daily software (version 21.2.1.455), which was used for peak integration and quantification by peptide ratios. QC SRM data were manually evaluated in Skyline by assessing retention time reproducibility, matching light and heavy transitions using Ratio Dot Product, and determining the peptide ratio precision using CV by QC condition. If Skyline could not automatically pick a consistent peak due to interference in the light transitions the peptide was removed from the analysis. Transition profiles were checked to insure the heavy and light transition profiles matched using the Ratio

209 Dot Product value in Skyline. The Ratio Dot Product (1 = exact match) is a measure of whether 210 the transition peak areas in the two label types are in the same ratio to each other. The average 211 Ratio Dot Product value for each peptide was >0.90 for each QCs. If the retention time or Ratio 212 Dot Product were outside of the expected range for a peptide in a few samples, the peaks 213 were checked individually and adjusted as necessary. Total area ratios for each peptide were 214 calculated in Skyline by summing the area for each light (3) and heavy (3) transition and 215 dividing the light total area by the heavy total area. The Total Area Ratio CV was assessed using 216 Skyline and the peptide was removed from the analysis if the CV>20% by QC condition. Next, 217 the individual CSF samples were analyzed in a blinded fashion. We used the total area ratios 218 (peptide ratios) for each targeted peptide in each sample and QC analysis; therefore, there are 219 no missing values in the Data Matrix on Synapse. The raw data files and Skyline file have been 220 deposited on Synapse<sup>22</sup>.

221

#### 222 Statistical analyses

223 We used Skyline-daily software (version 21.2.1.455) and GraphPad Prism (version 9.4.1) 224 software to calculate means, medians, standard deviations, and coefficients of variations<sup>24</sup>. 225 Peptide abundance ratios were log2-transformed, and zero values were imputed as one-half 226 the minimum nonzero abundance measurement. Then, one-way ANOVA with Tukey post hoc 227 tests for significance of the paired groupwise differences across diagnosis groups was 228 performed in R (version 4.0.2) using a custom calculation and volcano plotting framework 229 implemented and available as an open-source set of R functions documented further on 230 https://www.github.com/edammer/parANOVA. T test p values and Benjamini-Hochberg FDR 231 for these are reported for two total group comparisons, as was the case for AT+ versus AT-232 peptide mean difference significance calculations. Receiver-operating characteristic (ROC) 233 analysis was performed in R (version 4.0.2) with a generalized linear model binomial fit of each 234 set of peptide ratio measurements to the binary case diagnosis subsets AD/Control, 235 AsymAD/Control, and AD/AsymAD using the pROC package implementing ROC curve plots, 236 and calculations of AUC and AUC DeLong 95% confidence interval. Additional ROC curve 237 characteristics including sensitivity, specificity, and accuracy were calculated with the 238 reportROC R package. Robustness of the ROC calculations of AUC were confirmed using k-fold 239 cross validation (k=10 folds, with each fold containing case subsets with equal distributions of the binary outcome) implemented using the cvAUC R package functions for calculating cross-240 241 validated AUC (cvAUC), and confidence interval on pooled predictions, and these calculations 242 were consistently within 1 percent of AUC as calculated using a single calculation on the full 243 data (data not shown). Venn diagrams were generated using the R vennEuler package, and the 244 heatmap was produced using the R pheatmap package/function. R boxplot function output 245 was overlaid with beeswarm-positioned individual measurement points using the R beeswarm 246 package. Pearson correlations of SRM peptide measurements to immunoassay measurements 247 of Aβ(1-42), total Tau, phospho-T181 Tau, and the ratio of total Tau/ Aβ were performed using 248 the corAndPvalue WGCNA function in R. Correlation scatterplots were generated using the 249 verboseScatterplot WGCNA function.

250

#### 251 Data Records

252

All files have been deposited on Synapse<sup>22</sup>. The data folder contains sample traits, transition 253 254 details, the peptide ratio data matrix, transition ratios, and protein details. The Metadata file 255 contains the available traits for each sample analyzed including: SampleID – Internal Sample 256 Identifier; Age(years) – Deidentified Age in years; Sex – Binary Sex; Race – self identified race; 257 Educ – formal years of education; MoCA – Montreal Cognitive Assessment Score ranging from 258 0-30; APOE status – APOE genotype; Aβ42, tTau, pTau – as measured in CSF by Roche Elecsys® 259 immunoassay platform; tTau:A $\beta$ 42 – ratio of tTau/ A $\beta$ 42; SampleRunOrder – the order the 260 samples were acquired; Condition – the Control/AsymAD/AD group used in the analysis. The

261 DataMatrix file contains peptide ratio data for each sample. Data file names are list in the top 262 row of the DataMatrix: AT+ QC samples begin with AD\_; AT- QC samples begin with CTL\_; 263 Individual samples can be mapped back to the Metadata using the sample run order (Sxxx) or 264 SampleID (\_xxxxx); Plate/box and well position also defined in the file name (\_Bx\_Axx). The 265 MS RAW files folder contains all mass spectrometry raw files (N=423) from both quality control 266 replicates and clinical samples. The Skyline quantification folder contains the Skyline file that 267 was used to report the peptide ratios, calculate CVs and means, and ratio dot product.

268

### 269 **Technical Validation**

270

#### 271 Assessing peptide precision using pooled CSF quality control (QC) standards

272 We generated two pools of CSF reference standards as QCs based on biomarker status (AT-273 and AT+). These QCs were processed and analyzed (at the beginning, end, and after every 20 274 samples per plate) identically to the individual clinical samples for testing assay reproducibility. 275 We analyzed 30 QCs (15 AT- and 15 AT+) over approximately 5 days during the run of clinical 276 samples. We identified 62 peptides from 51 proteins as reliably measured in the pooled 277 reference standards. Notably, only 5 of these peptides overlap with previous published PRM 278 dataset given the unique differences in sample preparation, MS platform and peptide 279 selection<sup>21</sup>. We included 58 peptides from 51 proteins in our biomarker analysis, plus peptides 280 specific for the four APOE alleles for proteogenomic confirmation of APOE genotypes<sup>27,28</sup>. The 281 technical coefficient of variation (CV) of each peptide was calculated based on the peptide 282 area ratio for the biomarker negative (AT-) and positive (AT+) QCs. We defined CSF peptide biomarkers with CVs ≤ 20% as quantified with high precision in these technical replicates which 283 284 were un-depleted and unfractionated CSF sample pools. Technical and process reproducibility 285 for all reported peptides was below 20% (CV < 20%) in at least one pooled reference standard. 286 The average CVs for all peptides in the AT- and AT+ QCs were 13% and 12%, respectively. 287 Supplemental Table 1 contains the QC statistics for the biomarker and APOE allele specific 288 peptides. Levels of HBA and HBB peptides can be used to assess the levels of potential blood contamination<sup>29</sup> in each of the CSF samples across individual plates (Supplemental Fig. 1). 289 290 Correction for blood contamination could improve the statistics; however, no correction was 291 performed for the statistical analyses presented. We used the protein directions of change to 292 assess accuracy in the QC pools. The volcano plot between peptides measured in the pools 293 highlights peptide/protein levels that are consistent with previously reported AD biomarkers 294 (Supplemental Fig. 2)<sup>16,21</sup>.

295

#### 296 Monitoring LC-MS/MS instrument performance

297 The sample reconstitution solution contained Promega 6×5 LC-MS/MS Peptide Reference Mix 298 (50 fmol/µL)<sup>30</sup>. The Promega Peptide Reference Mix provides a convenient way to assess LC 299 column performance and MS instrument parameters, including sensitivity and dynamic range. 300 The mix consists of 30 peptides; 6 sets of 5 isotopologues of the same peptide sequence, 301 differing only in the number of stable, heavy-labeled amino acids incorporated into the 302 sequence using uniform 13C and 15N atoms making them chromatographically 303 indistinguishable. The isotopologues were specifically synthesized to cover a wide range of 304 hydrophobicities so that dynamic range could be assess across the gradient profile (Fig. 2A). 305 Each isotopologue represents a series of 10-fold dilutions, estimated to be 1 pmole, 100 fmole, 306 10 fmole, 1 fmole, and 100 amole for each peptide sequence in a 20  $\mu$ L injection, a range that 307 would challenge the lowest limits of detection of the method (Fig. 2B). We assessed the raw 308 peak areas in 423 injections over 5 days to determine the label-free CV for each peptide 309 isotopologue (Fig. 2B). The 100-amole level (0.0001x) was not detected (ND) for any of the 310 peptide sequences. Based on the label-free CV, we determined the lowest limit of detection 311 for each peptide to be between 1-10 fmole across the gradient profile with a dynamic range

spanning 4 orders of magnitude for all peptides except the latest eluting peptide at 13.3minutes (Fig. 2C).

314

#### 315 Technical replicate variance

Three individual samples were analyzed in duplicate scattered throughout the sample run sequence to assess technical replicate variance. We graphed the log2(ratio) for each of 58 biomarker peptides in replicate 1 versus replicate 2 for each sample and determined the Pearson correlation coefficient with associated P value (**Supplemental Fig. 3**). The analysis showed a near-identical correlation (p=0.996-0.998; p<1e-200) between each of the technical replicate pairs for the three individual CSF samples, supporting the same high level of method reproducibility we found using the QC pools.

323

#### 324 Concordance between a discovery (ssTMT) and replication (SRM) datasets

325 Since our peptide targets were largely based on multiple ssTMT datasets<sup>16</sup>, we generated a 326 representative ssTMT peptide level volcano from one of these datasets comprised of 297 327 individuals (147 control and 150 AD) (Fig. 3A). There are 44 of 62 SRM peptides that overlap 328 with this ssTMT dataset and are highlighted in yellow on the volcano plot (Fig. 3A). To establish 329 peptide concordance, we also compared the direction of change or effect size (log2 fold 330 change) for 40 overlapping peptides, excluding albumin, hemoglobin, and APOE allele specific 331 peptides. Fig. 3B shows significant correlation (cor = 0.91; p = 2.8e-15) between SRM and 332 ssTMT peptide highlighting the accuracy and concordance of measurements across both MS 333 assays. Thus, despite substantial differences in chromatography (nanoflow versus standard 334 flow), MS instrumentation (Orbitrap versus triple quadrupole), and protein quantitation 335 approaches (ssTMT versus SRM), the selected peptides in this assay are highly reproducible 336 and robust in their direction of change in AD CSF.

337

## 338 Usage Notes

This targeted mass spectrometry dataset serves as a valuable resource for a variety of research
 endeavors including, but not limited to, the following applications:

#### 341 Use case 1: Peptide abundance in CSF

This dataset provides a reference for peptide detectability in CSF under relatively highthroughput conditions, especially if an investigator wants to determine whether their protein of interest has abundance above the lower limit of detection in CSF under these analytical conditions. Raw data deposited on Synapse<sup>22</sup> contains transitions for over 200 peptides that were robustly detected in CSF discovery proteomics<sup>16,21</sup>.

#### 347 Use case 2: Using APOE allele specific peptides for genotyping

348 Apolipoprotein E (ApoE) has three major genetic variants (E2, E3, and E4, encoded by the  $\epsilon$ 2,  $\epsilon$ 3 and  $\epsilon$ 4 alleles, respectively) that differ by single amino acid substitutions<sup>31</sup>. APOE genotype 349 is closely related to AD risk<sup>32</sup> with ApoE4 having the highest risk, ApoE2 the lowest risk, and 350 351 ApoE3 with intermediate risk<sup>33,34</sup>. Due to the amino acid substitutions in each variant, there 352 are allele specific peptides that can be targeted by mass spectrometry<sup>27,35</sup>. We monitored 353 CLAVYQAGAR (APOE2), LGADMEDVR (APOE4), LGADMEDVCGR (APOE2 or APOE3), and 354 LAVYQAGAR (APOE3 or APOE4) to confirm the APOE genotype of each CSF sample in a 355 concurrent SRM-MS method<sup>22</sup>. The CV for each APOE peptide in each QC is listed in 356 **Supplemental Table 1**. Previous studies report the association of APOE genotype with various clinical, neuroimaging, and biomarker measures<sup>36-39</sup>. Exploring the relationship between APOE 357 358 status and the CSF biomarker peptides presented requires further analysis reserved for future 359 studies.

#### 360 Use case 3: Stage-specific differences in peptide and protein levels

361 The described cohort includes control, AsymAD, and AD groups across the Amyloid/Tau/Neurodegeneration (AT/N) framework $^{40}$ , which allows for the comparison of 362 363 peptide and protein differential abundance across stages of disease. Investigators can focus 364 on comparisons that are specific to symptomatic AD or those with potential for staging AD by 365 using the AsymAD group compared to the control group. By comparing candidate biomarkers 366 using ANOVA (excluding APOE allele specific peptides), we found 41 differentially expressed 367 peptides (36 proteins) in AsymAD vs controls (Fig. 4A), 35 differentially expressed peptides (30 368 proteins) in AD versus controls (Fig. 4B), and 21 differentially expressed peptides (18 proteins) 369 in AD vs AsymAD (Fig. 4C). The Venn diagram summarizes the differentially expressed peptides 370 across groups in Fig. 4D.

371 Using a differential abundance analysis, we were able to stratify the changing proteins as early 372 or progressive biomarkers of AD (Fig. 4 and 5). The log<sub>2</sub>-fold change (Log<sub>2</sub> FC) from the volcano 373 plots in Fig. 4 are represented as a heatmap in Fig. 5A to illustrate how each peptide is 374 changing across each group comparison. Twenty-two peptides (21 proteins) were early 375 biomarkers of AD because they were significantly different in AsymAD versus controls, but not 376 significantly different in AD versus AsymAD (Fig. 5A). A plurality of these proteins mapped to metabolic enzymes linked to glucose metabolism (PKM, MDH1, ENO1, ALDOA, ENO2, LDHB, 377 and TPI1, also in Supplemental Table 2)<sup>13,14</sup>. SMOC1 and SPP1, markers linked to glial biology 378 379 and inflammation<sup>14,16</sup>, were also increased in AsymAD samples compared to controls (Fig. 5B, 380 top row). GAPDH, YWHAB and YWHAZ proteins were found to be progressive biomarkers of 381 AD because the proteins were differentially expressed from Control to AsymAD and from 382 AsymAD to AD with a consistent trend in direction of change (Fig. 5B, middle row). Proteins 383 associated with neuronal/synaptic markers including VGF, NPTX2, NPTXR, and L1CAM were 384 increased in AsymAD compared to controls but decreased in AD vs controls (Fig. 5B, lower 385 row). Interestingly, we found 14 peptides (13 proteins) that were up in AsymAD as compared 386 to Control but down in AD when compared to AsymAD. A majority of these proteins map to 387 neuronal/synaptic markers including VGF, NPTX2, NPTXR, which are some of the most 388 correlated proteins in post-mortem brain to an individual's slope of cognitive trajectory in life 389 (Fig. 5A and 5B, lower row)<sup>41</sup>.

#### 390 Use case 4: Correlation of peptide biomarker abundance to A $\beta$ (1-42), Tau, pTau and 391 cognitive measures

392 The comparison of existing biomarkers to the SRM peptide measurements can be 393 accomplished by correlation, where the degree of correlation indicates how similar a peptide 394 measurement is to the established immunoassay-measured biomarkers of A $\beta$ (1-42), total Tau, 395 and pTau as well as cognition (MoCA score). In Fig. 6A, we demonstrate that 57 of the 58 396 biomarker peptides have significant correlation to at least one of the above biomarkers, or the 397 ratio of total Tau/A $\beta$ . Individual correlation scatterplots and linear fit lines for three of the 398 peptides (SMOC1: AQALEQAK, YWHAZ: VVSSIEQK, and VGF: EPVAGDAVPGPK) are provided in 399 Fig. 6B. Significant correlations of these peptides to the established biomarker and cognitive 400 measures indicate the potential of these measurements to classify or stage disease 401 progression. The targeted SRM measurement correlations largely agree with those observed from unbiased discovery proteomics<sup>42</sup> and parallel reaction monitoring<sup>21</sup> experiments. 402

#### 403 Use case 5: Receiver-operating characteristic (ROC) analysis for evaluating biomarker 404 diagnostic capability

The capacity for peptide measurements to serve as a diagnostic biomarker distinguishing individuals with AD and even asymptomatic disease from individuals not on a trajectory to develop AD is well-established, with secreted amyloid and tau peptide measurements in CSF being the current gold standard for interrogation of patients' AD stage from their CSF<sup>43</sup> where CSF A $\beta$ (1-42) concentration inversely correlates to plaque deposition in the living brain<sup>44</sup>. The measurements of additional peptides collected here are appropriate for comparison to

411 immunoassay measurements of CSF amyloid and Tau biomarker positivity, or a dichotomized 412 cognition rating, or other ancillary traits such as diagnosis for the 390 individuals. To 413 demonstrate this utility, we performed receiver-operating characteristic (ROC) curve analysis 414 and calculated the area under the curve (AUC) for all 62 peptide measures as fitting a logistic 415 regression to 3 subsets of samples divided to represent known pairs of disease stages, namely 416 AD versus control, AsymAD versus control, and AD vs AsymAD (Fig. 7 and Supplemental Table 417 4). The top performing peptide for the YWHAZ gene product 14-3-3 ζ protein demonstrated 418 an AUC of 89.5% discrimination of AD from control cases consistent with previous studies<sup>21,45,46</sup>. SMOC1 AUC of 81.8% was the best performing peptide for discrimination of 419 420 AsymAD from control groups. In contrast, the synaptic peptides to NPTX2 (AUC of 74.0%), 421 NPTXR (AUC of 71.1%), VGF (AUC of 70.1%) and SCG2 (AUC of 69.8%) best discriminated AD 422 from AsymAD groups suggesting that neurodegeneration due to AD pathology is occurring in 423 the symptomatic phase of disease<sup>47</sup>. Fig. 7 shows the top five peptides by AUC for each of the three comparisons, highlighting the potential of this data set to aid in the design or validation 424 425 of stage-specific biomarkers. Additional future analysis using these peptides alone or in 426 combination could be used to subtype, predict disease onset, and gauge treatment efficacy.

## 427 Code Availability

Custom code generating use case figures and tables including correlation plots, volcanoes, Venn diagram, annotated heatmap, statistics tables, and ROC curves is available for download with registration for a free account on synapse.org. The code is available as R scripts from <u>https://doi.org/10.7303/syn35927166</u> (the Analysis folder) deposited on Synapse<sup>22</sup>. These scripts were run as provided on R version 4.0.2 with the two provided input files to generate outputs.

434

## 435 Acknowledgements

This study was supported by the following National Institutes of Health funding mechanisms:
U01AG061357 (A.I.L and N.T.S), R01AG070937-01 (J.J.L) and P30AG066511 (A.I.L). We
acknowledge our colleagues at Emory for providing critical feedback.

#### 439 440 Author contributions

Conceptualization, C.M.W., L.P., D.M.D., J.J.L., A.I.L., B.R.R, N.T.S.; Methodology, C.M.W.,
E.B.D, L.P., D.M.D., E.M., E.K.C., B.R.R, N.T.S.; Investigation and Formal Analysis, C.M.W., E.B.D,
L.P., D.M.D., B.R.R, N.T.S.; Writing – Original Draft, C.M.W., E.B.D., N.T.S.; Writing – Review
and Editing, C.M.W., E.C.B.J, B.R.R., J.J.L., A.I.L., N.T.S.; Funding Acquisition, A.I.L. and N.T.S.;
Supervision, N.T.S.

446

## 447 **Competing interests**

448 The authors declare no competing interests.

449

## 450 Figure Legends

451

452 Figure 1. Cohort characteristics. A total of 390 samples (133 controls, 127 AsymAD, 130 AD 453 unless otherwise noted) were analyzed using the following characteristics for grouping. (A) 454 Age range across each group of the cohort was carefully selected to balance for age and sex 455 (Supplemental Table 1). (B) Cognition was assessed using the Montreal Cognitive Assessment 456 (MoCA) score; there is no significant difference in scores between the Control and AsymAD 457 groups serving as the two cognitively normal diagnostic groups (133 controls, 127 AsymAD, 458 124 AD). The Roche Diagnostics Elecsys<sup>®</sup> platform was used for CSF biomarker measurements 459 for A $\beta$ (1-42) (**C**), Total Tau (133 controls, 127 AsymAD, 129 AD) (**D**), and pTau (**E**) (pg/mL) 460 showing the significance between groups for each measurement. (F) Tau/A $\beta$  ratio data across

461 control, AsymAD and AD groups. There was no significant difference between AsymAD and AD
 462 groups to serve as our biomarker positive groups (133 controls, 127 AsymAD, 129 AD). The
 463 significance of the pairwise comparisons is indicated by overlain annotation of 'ns' (not
 464 significant; p>0.05) or asterisks; \*\*\*\*p≤0.0001.

465

466 Figure 2. Isotopologue peptide internal reference standards to determine consistency of LC-467 MS/MS platform. Each of the CSF samples were spiked with a six-peptide, 5 isotopologue 468 concentration LC-MS/MS Peptide Reference Mix from Promega (50 fmol/ $\mu$ L). (A) Extracted ion 469 chromatogram for the 6 peptide (1pmol) mixture illustrating the wide range of retention times 470 due to their hydrophobicity. (B) The raw peak areas in 423 injections over 5 days were used to 471 determine the label-free CV for each peptide isotopologue estimating the lowest limits of 472 detection to be between 1-10 fmole for each peptide. (C) The 5 unique isotopologues are used 473 to assess the dynamic range across the gradient profile and each peptide demonstrates linearity across 3-4 orders of magnitude in the batch of 423 injections. Error bars represent 474 475 the standard deviation across 423 injections.

476 Figure 3. Peptide concordance between SRM and ssTMT datasets. (A) Volcano plot displaying 477 the log<sub>2</sub> fold change (FC) (x-axis) against t-test log10 p-value (y-axis) for all peptides (n=2,340) 478 comparing AD (n=150) versus Controls (n=147). Cutoffs were determined by significant 479 differential expression (p<0.05) between control and AD cases. Peptides with significantly 480 decreased levels in AD are shown in blue while peptides with significantly increased levels in 481 disease were indicated in red. 44 of 62 SRM peptides that overlap with this ssTMT dataset and 482 SRM are highlighted as larger yellow points with black text labels. Red text and traces to red 483 points are labels for peptides not included in the current SRM study that were significantly 484 upregulated in the ssTMT dataset. (B) Correlation between the fold-change (AD vs control) of 485 all selected overlapping peptides (n=40) across SRM (x-axis) and ssTMT (y-axis) were strongly 486 correlated (cor=0.91, p=2.8e-15).

487

488 Figure 4. Differential expression analysis across stages of AD. ANOVA analysis with Tukey post 489 hoc FDR was performed for pairwise comparison of mean log<sub>2</sub>(ratio) differences between the 490 3 stages of AD (i.e., Control, AsymAD and AD) of N=390 total case samples and plotted as a 491 volcano. Significance threshold for counting of peptides was p < 0.05 (dashed horizontal line). 492 Differentially expressed peptides for (A) AsymAD (N=127) versus control (N=133), (B) AD 493 (N=130) versus control, and (C) AD versus AsymAD are labeled by their gene symbols. (D) 494 Counts of peptides with significant difference in any of the 3 dichotomous comparisons are 495 presented as a Venn diagram. Full statistics from the ANOVA and Tukey post-hoc analysis is 496 presented in Supplemental Table 2.

497

498 Figure 5. Stratifying early from progressive biomarkers of AD. (A) The magnitude of positive 499 (red) and negative (blue) changes are shown on a gradient color scale heatmap representing 500 mean log<sub>2</sub>-fold change (Log<sub>2</sub>FC) for each of 49 peptides significant in any of the 3 group 501 comparisons. Tukey significance of the pairwise comparisons is indicated by overlain asterisks; 502 \*p<0.05, \*\*p<0.01, \*\*\*p<0.001. (B) Peptide abundance levels of selected panel markers that 503 are differentially expressed between groups. The upper row highlights biomarkers that are 504 significantly different in AsymAD versus controls, but not significantly different in AsymAD 505 versus AD. The middle row of 3 peptides highlights progressive biomarkers of AD, which show 506 a stepwise increase in abundance from control to AsymAD to AD cases. The bottom row 507 highlights a set of proteins that are increased in AsymAD compared to controls but decreased 508 in AD versus control or AsymAD samples.

509

510 Figure 6. Correlating CSF peptide biomarker abundances to amyloid, Tau, and cognitive 511 measures. (A) Positive (red) and negative (blue) Pearson correlations between biomarker 512 peptide abundance and immunoassay measures of  $A\beta(1-42)$ , total Tau, phospho-T181 Tau 513 (pTau), ratio of total Tau/A $\beta$  and cognition (MoCA score). Student's t test significance is 514 indicated by overlain asterisks; \*p<0.05, \*\*p<0.01, \*\*\*p<0.001. (B) Individual correlation 515 scatterplots are shown for SMOC1 (upper row), YWHAZ (middle row), and VGF (lower row). 516 Individual cases are colored by their diagnosis; blue for controls, red for AsymAD cases, and 517 green for AD cases. Amyloid immunoassay measures of 1,700 (maximum, saturated value in 518 the assay) were not considered for correlation.

519

520 Figure 7. Receiver-operating characteristic (ROC) curve analysis of peptide diagnostic 521 potential. ROC curves for each of three pairs of diagnosed case groups were generated to 522 determine the top-ranked diagnostic biomarker peptides among the 58-peptide panel plus 4 APOE specific peptides. (A) A total of 263 AD (N=130) and control (N=133) CSF case samples 523 524 were classified according to the logistic fit for each peptide's log<sub>2</sub>(ratio) measurements across 525 these samples, and the top 5 ranked by AUC are shown. (B) Top five performing peptides for 526 discerning AsymAD (N=127) from control (N=133) case diagnosis groups are provided with 527 AUCs, nominating these peptides as potential markers of pre-symptomatic disease, and as 528 cognates for AT+ biomarker positivity. (C) Symptomatic AD (N=130) and AsymAD (N=127) 529 discerning peptides were ranked by AUC and the top five ROC curves are shown and 530 nominated as cognate CSF measures for compromised patient cognition.

531

## 532 Supplemental Data

533

Supplemental Figure 1. Monitoring background peptide levels in CSF. Three proteins were
 monitored for levels of potential blood contamination in each of the CSF samples. The peptide
 ratio for hemoglobin subunit alpha (A), hemoglobin subunit beta (B), and albumin (C and D)
 peptides are plotted for each of the CSF samples (N=423) in acquisition order.

538

539 Supplemental Figure 2. Differentially abundant peptides representing changed proteins in 540 AT- vs AT+ QC CSF pools. The differentially abundant proteins in the QC pools were used to 541 check the accuracy of the fold change consistent with our other studies<sup>16</sup>. We found 21 542 upregulated and 10 downregulated peptides. This result validated the direction of change of 543 six proteins nominally significantly downregulated in previously published discovery 544 proteomics (PON1, APOC1, NPTX2, VGF, NPTXR, and SCG2), and of sixteen proteins previously 545 reported as upregulated (YWHAZ, GDA, CHI3L1, PKM, CALM2, SMOC1, YWHAB, MDH1, 546 ALDOA, ENO1, GOT1, PPIA, DDAH1, PEBP1, PARK7, and SPP1)<sup>16,21</sup>.

547

548 Supplemental Figure 3. Technical reproducibility of peptide measurements in replicate CSF 549 samples. Pearson correlation and p-value of replicate measures of 58 peptides in the 3 550 replicated CSF samples that were analyzed randomly within the series of 423 injections by 551 SRM-MS.

552

Supplemental Table 1. Coefficient of variation (CV) values for 58 biomarker peptides and APOE
 allele specific peptides in AT- and AT+ QC pools.

555

Supplemental Table 2. ANOVA of differential abundance analysis for 58 biomarker peptides
 across Control, AsymAD and AD sample pairwise group comparisons. The SRM proteins were
 also cross-referenced with protein data and module membership from Johnson et al.
 Consensus Network<sup>48</sup>, and mapped to CSF protein panels from Higginbotham et al. Integrated
 Proteomic analysis<sup>16</sup>.

561

562 **Supplemental Table 3.** Pearson correlations (rho), Student p values of correlation significance, 563 and numbers of paired observations for correlation of biomarker peptide abundances to 564 immunoassay measures of  $A\beta(1-42)$ , total Tau, phospho-T181 Tau, and the ratio of total Tau/ 565  $A\beta$ .

566

Supplemental Table 4. ROC curve statistics including AUC, p, 95% DeLong confidence interval,
 accuracy, specificity, and sensitivity for dichotomous diagnosis case sample groups.

#### 570 **References**

571

569

572 1 Scheltens, P. *et al.* Alzheimer's disease. *The Lancet* **397**, 1577-1590, doi:10.1016/S0140-6736(20)32205-4 (2021).

574 2 Duyckaerts, C., Delatour, B. & Potier, M.-C. Classification and basic pathology of 575 Alzheimer disease. *Acta neuropathologica* **118**, 5-36 (2009).

- 5763Jack Jr, C. R. *et al.* NIA-AA research framework: toward a biological definition of577Alzheimer's disease. Alzheimer's & Dementia 14, 535-562 (2018).
- 5784Mattsson-Carlgren, N. *et al.* Cerebrospinal fluid biomarkers in autopsy-confirmed579Alzheimer disease and frontotemporal lobar degeneration. *Neurology* **98**, e1137-580e1150 (2022).
- 581 5 Zetterberg, H. & Blennow, K. Moving fluid biomarkers for Alzheimer's disease from 582 research tools to routine clinical diagnostics. *Molecular neurodegeneration* **16**, 1-7 583 (2021).
- 584 6 Long, J. M. & Holtzman, D. M. Alzheimer disease: an update on pathobiology and 585 treatment strategies. *Cell* **179**, 312-339 (2019).
- 5867Rayaprolu, S. *et al.* Systems-based proteomics to resolve the biology of Alzheimer's587disease beyond amyloid and tau. *Neuropsychopharmacology* **46**, 98-115 (2021).
- Sperling, R. A. *et al.* Toward defining the preclinical stages of Alzheimer's disease:
  Recommendations from the National Institute on Aging-Alzheimer's Association
  workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & dementia*7, 280-292 (2011).
- 592 9 Dubois, B. *et al.* Preclinical Alzheimer's disease: definition, natural history, and 593 diagnostic criteria. *Alzheimer's & Dementia* **12**, 292-323 (2016).
- Hasin, Y., Seldin, M. & Lusis, A. Multi-omics approaches to disease. *Genome biology* **18**, 1-15 (2017).
- 59611Seyfried, N. T. *et al.* A Multi-network Approach Identifies Protein-Specific Co-597expression in Asymptomatic and Symptomatic Alzheimer's Disease. *Cell Syst* 4, 60-72598e64, doi:10.1016/j.cels.2016.11.006 (2017).
- Johnson, E. C. B. *et al.* Deep proteomic network analysis of Alzheimer's disease brain
  reveals alterations in RNA binding proteins and RNA splicing associated with disease. *Mol Neurodegener* 13, 52, doi:10.1186/s13024-018-0282-4 (2018).
- Johnson, E. C. B. *et al.* A Consensus Proteomic Analysis of Alzheimer's Disease Brain
  and Cerebrospinal Fluid Reveals Early Changes in Energy Metabolism Associated with
  Microglia and Astrocyte Activation. *bioRxiv*, 802959, doi:10.1101/802959 (2019).
- 60514Johnson, E. C. *et al.* Large-scale proteomic analysis of Alzheimer's disease brain and606cerebrospinal fluid reveals early changes in energy metabolism associated with607microglia and astrocyte activation. Nature medicine 26, 769-780 (2020).
- 60815Blennow, K. & Zetterberg, H. Biomarkers for Alzheimer's disease: current status and609prospects for the future. Journal of internal medicine 284, 643-663 (2018).
- 610 16 Higginbotham, L. *et al.* Integrated proteomics reveals brain-based cerebrospinal fluid
  611 biomarkers in asymptomatic and symptomatic Alzheimer's disease. *Science advances*612 6, eaaz9360 (2020).

- Picotti, P. & Aebersold, R. Selected reaction monitoring–based proteomics: workflows,
  potential, pitfalls and future directions. *Nature methods* 9, 555-566 (2012).
- 615 18 Bittner, T. et al. Technical performance of a novel, fully automated 616 electrochemiluminescence immunoassay for the quantitation of beta-amyloid (1-42) 617 human cerebrospinal fluid. Alzheimers Dement 12, in 517-526, doi:10.1016/j.jalz.2015.09.009 (2016). 618
- 619 19 Hansson, O. et al. CSF biomarkers of Alzheimer's disease concord with amyloid-beta 620 PET and predict clinical progression: A study of fully automated immunoassays in 621 BioFINDER and ADNI cohorts. Alzheimers Dement 14, 1470-1481, 622 doi:10.1016/j.jalz.2018.01.010 (2018).
- 62320Schindler, S. E. *et al.* Cerebrospinal fluid biomarkers measured by Elecsys assays624compared to amyloid imaging. Alzheimers Dement, doi:10.1016/j.jalz.2018.01.013625(2018).
- 21 Zhou, M. *et al.* Targeted mass spectrometry to quantify brain-derived cerebrospinal
  fluid biomarkers in Alzheimer's disease. *Clinical Proteomics* 17, 1-14 (2020).
- Watson, C. M., Dammer, E.B., and Seyfried, N.T. Emory AD CSF SRM. *Synapse*,
   doi:<u>https://doi.org/10.7303/syn34054965</u> (2022).
- MacLean, B. *et al.* Skyline: an open source document editor for creating and analyzing
  targeted proteomics experiments. *Bioinformatics* 26, 966-968 (2010).
- Pino, L. K. *et al.* The Skyline ecosystem: Informatics for quantitative mass spectrometry
  proteomics. *Mass spectrometry reviews* **39**, 229-244 (2020).
- 63425MacLean, B. et al. Effect of collision energy optimization on the measurement of635peptides by selected reaction monitoring (SRM) mass spectrometry. Analytical636chemistry 82, 10116-10124 (2010).
- Kulak, N. A., Pichler, G., Paron, I., Nagaraj, N. & Mann, M. Minimal, encapsulated
  proteomic-sample processing applied to copy-number estimation in eukaryotic cells. *Nature methods* 11, 319-324 (2014).
- 64027Simon, R. *et al.* Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-641control study by targeted mass spectrometry (n= 669): a pilot assay for methionine-642containing proteotypic peptides. *Molecular & Cellular Proteomics* **11**, 1389-1403643(2012).
- Rezeli, M. *et al.* Quantification of total apolipoprotein E and its specific isoforms in
  cerebrospinal fluid and blood in Alzheimer's disease and other neurodegenerative
  diseases. *EuPA Open Proteomics* 8, 137-143 (2015).
- 647 29 Geyer, P. E. *et al.* Plasma Proteome Profiling to detect and avoid sample-related biases
  648 in biomarker studies. *EMBO molecular medicine* **11**, e10427 (2019).
- 64930Beri, J., Rosenblatt, M. M., Strauss, E., Urh, M. & Bereman, M. S. Reagent for evaluating650liquid chromatography-tandem mass spectrometry (LC-MS/MS) performance in651bottom-up proteomic experiments. Analytical chemistry 87, 11635-11640 (2015).
- Hatters, D. M., Peters-Libeu, C. A. & Weisgraber, K. H. Apolipoprotein E structure:
  insights into function. *Trends in biochemical sciences* **31**, 445-454 (2006).
- 65432Saunders, A. M. *et al.* Association of apolipoprotein E allele ε4 with late-onset familial655and sporadic Alzheimer's disease. Neurology 43, 1467-1467 (1993).
- Farrer, L. A. *et al.* Effects of age, sex, and ethnicity on the association between
  apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and
  Alzheimer Disease Meta Analysis Consortium. *JAMA* 278, 1349-1356 (1997).
- Heffernan, A. L., Chidgey, C., Peng, P., Masters, C. L. & Roberts, B. R. The neurobiology
  and age-related prevalence of the ε4 allele of apolipoprotein E in Alzheimer's disease
  cohorts. *Journal of Molecular Neuroscience* 60, 316-324 (2016).
- Minta, K. *et al.* Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases. *Alzheimer's research & therapy* 12, 1-11 (2020).

665 666 667	36	Bussy, A. <i>et al.</i> Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. <i>Neuropiology of gaing</i> <b>75</b> , 42-50 (2019).					
668	37	Fl-Lebedy D Raslan H M & Mohammed A M Apolipoprotein Egene polymorphism					
669	07	and risk of type 2 diabetes and cardiovascular disease. <i>Cardiovascular diabetology</i> <b>15</b> ,					
670		1-11 (2016).					
671	38	Morris, J. C. et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in					
672		cognitively normal aging. Ann Neurol 67, 122-131, doi:10.1002/ana.21843 (2010).					
673	39	Grimmer, T. et al. Progression of cerebral amyloid load is associated with the					
674		apolipoprotein E ε4 genotype in Alzheimer's disease. <i>Biological psychiatry</i> <b>68</b> , 879-884					
675		(2010).					
676	40	Knopman, D. S. et al. The National Institute on Aging and the Alzheimer's Association					
677		research framework for Alzheimer's disease: perspectives from the research					
678		roundtable. Alzheimer's & Dementia 14, 563-575 (2018).					
679	41	Wingo, A. P. et al. Large-scale proteomic analysis of human brain identifies proteins					
680		associated with cognitive trajectory in advanced age. Nature communications 10, 1-					
681		14 (2019).					
682	42	Dammer, E. B. et al. Multi-Platform Proteomic Analysis of Alzheimer's Disease					
683		Cerebrospinal Fluid and Plasma Reveals Network Biomarkers Associated with					
684		Proteostasis and the Matrisome. <i>bioRxiv</i> (2022).					
685	43	Bertens, D., Knol, D. L., Scheltens, P. & Visser, P. J. Temporal evolution of biomarkers					
686		and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's					
687		disease. Alzheimer's & Dementia <b>11</b> , 511-522,					
688		doi: <u>https://doi.org/10.1016/j.jalz.2014.05.1754</u> (2015).					
689	44	Shokouhi, S. et al. Reference tissue normalization in longitudinal 18F-florbetapir					
690		positron emission tomography of late mild cognitive impairment. Alzheimer's					
691		<i>Research &amp; Therapy</i> <b>8</b> , 2, doi:10.1186/s13195-016-0172-3 (2016).					
692	45	Sathe, G. et al. Quantitative proteomic profiling of cerebrospinal fluid to identify					
693		candidate biomarkers for Alzheimer's disease. <i>PROTEOMICS–Clinical Applications</i> 13,					
694		1800105 (2019).					
695	46	Bader, J. M. <i>et al.</i> Proteome profiling in cerebrospinal fluid reveals novel biomarkers					
696	47	of Alzheimer's disease. <i>Molecular systems biology</i> <b>16</b> , e9356 (2020).					
697	47	Libiger, O. et al. Longitudinal CSF proteomics identifies NPTX2 as a prognostic					
698		biomarker of Alzheimer's disease. Alzheimer's & Dementia 17, 1976-1987 (2021).					
699	48	Johnson, E. C. et al. Large-scale deep multi-layer analysis of Alzheimer's disease brain					
700		reveals strong proteomic disease-related changes not observed at the RNA level.					
701		Nature neuroscience <b>25</b> , 213-225 (2022).					
702							

Sample Group	СТ	AsymAD	AD	
Sample Size	N=133	N=127	N=130	
Characteristics				
Sex	99 F, 34 M	94 F, 33 M	97 F, 33 M	
Age ª	$66\pm 6$	$66\pm 6$	$66\pm6$	
MoCA <sup>b</sup>	$\textbf{26.8} \pm \textbf{2.0}$	$\textbf{26.4} \pm \textbf{2.6}$	$\textbf{17.4} \pm \textbf{5.5}$	
Αβ <sub>42</sub> <sup>b</sup>	$1394.0 \pm 280.7$	$\textbf{752.0} \pm \textbf{238.2}$	$587.0 \pm 236.8$	
tTau <sup>b</sup>	$165.8\pm35.0$	$\textbf{260.8} \pm \textbf{97.2}$	$\textbf{375.7} \pm \textbf{139.6}$	
pTau <sup>b</sup>	$14.7\pm3.2$	$\textbf{25.2} \pm \textbf{11.1}$	$38.5 \pm 15.5$	

Table 1. Cohort Characteristics

 $^{\rm a}$  Age in years. Values given as average  $\pm$  standard deviation

 $^{b}$  MoCA, AB $_{42}$ , tTau, and pTau in pg/mL. Values given in average  $\pm$  standard deviation

Abbreviations: CT, Control; AD, Alzheimer's disease; MoCA, Montreal Cognitive Assessment

Figure 1





0.1

1

Promega Peptide Sequence	Average Retention Time (min)	1 pmole (1x)	100 fmole (0.1x)	10 fmole (0.01x)	1 fmole (0.001x)	100 amole (0.0001x)
VTSGSTSTSR	1.42	17%	17%	18%	34%	ND
LASVSVSR	6.17	7%	8%	8%	17%	ND
YVYVADVAAK	8.83	11%	11%	13%	32%	ND
VVGGLVALR	10.65	8%	8%	9%	20%	ND
LLSLGAGEFK	11.75	9%	9%	10%	20%	ND
LGFTDLFSK	13.33	21%	21%	30%	ND	ND







В





# Figure 4





## Figure 5



Log2 FC

Α

# В



AsymAD-Control AD-Control AD-AsymAD



YWHAB|P31946|NLLSVAYK YWHAZ|P63104|VVSSIEQK YWHABIP31946IVISSIEOK SMOC1|Q9H4F8|AQALEQAK PKM|P14618|VVEVGSK GAPDH|P04406|YDNSLK PKM|P14618-2|LFEELVR GAPDH|P04406|AAFNSGK CALM2|P0DP24|EAFSLFDK CHI3L1|P36222|IASNTQSR MDH1|P40925|GEFVTTVQQR GDA|Q9Y2T3|DHLLGVSDSGK SPP1|P10451|QETLPSK ALDOA|P04075|VLAAVYK PARK7|Q99497|ALVILAK ENO1|P06733|LNVTEQEK ENO1|P06733|IEEELGSK PPIA|P62937|VSFELFADK GOT1|P17174|IGADFLAR ENO2|P09104|IEEELGDEAR PEBP1|P30086|VLTPTQVK DDAH1|O94760|EFFVGLSK LDHB|P07195|FIIPQIVK SOD1|P00441|HVGDLGNVTADK TPI1|P60174|IAVAAONCYK DKK3|Q9UBP4|DQDGEILLPR LAMP1|P11279|VWVQAFK LAMP2|P13473|YLDFVFAVK PTPRZ1|P23471|AIIDGVESVSR L1CAM|P32004|GQLSFNLR NCAM1|P13591|GLGEISAASEFK HBA1|P69905|FLASVSTVLTSK NRXN1|P58400|LAIGFSTVQK CD44|P16070|ALSIGFETCR OMG|P23515|LESLPAHLPR APOE|P02649|ELQAAQAR VGF|015240|GLQEAAEER SCG2|P13521|IESQTQEEVR VGF|015240|EPVAGDAVPGPK NPTXR|095502|ELDVLQGR GSN|P06396|AGALNSNDAFVLK DCN|P07585|VDAASLK OGN|P20774|LEGNPIVLGK NPTX2|P47972|VAELEDEK C9|P02748|TSNFNAAISLK C9|P02748|LSPIYNLVPVK APOA4|P06727|SLAPYAQDTQEK PGLYRP2|Q96PD5|TFTLLDPK F2|P00734|YTACETAR CP|P00450|GEFYIGSK KNG1|P01042|VQVVAGK APOC1IP02654IOSELSAK PON1|P27169|LLIGTVFHK VTN|P04004|GQYCYELDEK APOC2|P02655|TAAQNLYEK ALBIP02768ILVNEVTEFAK ALB|P02768|LVTDLTK



\*\*\* MoCA Aβ1–42 Total Tau pTau Tau/Aβ

Α

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*

\*

\*\*

\*

\*\*

\*

\*\*

\*\*

\*

\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*

×

\*\*\*

\*\*\*

\*\*\*

\*

0.6 0.4

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*

\*\*

\*\*

\*

\*\*

\*\*

\*\*\*

\*\*\*

\*\*

\*\*\*

\*\*\*

\*\*

\*\*\*

\*\*\*

Cor

0.2

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*

\*\*

\*\*

\*\*

\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*

\*\*\*

\*\*\*

\*\*

\*\*\*

0

-0.2

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*

\*

\*

¥

\*

\*

\*\*

\*\*

\*\*

\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*

\*\*\*

\*

\*\*\*

\*

\*\*\*

\*

\*\*

\*\*

\*\*\*

\*\*\*

\*\*\*

\*

\*

\*\*

\*

\*

\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

Figure 7



# **Supplemental Figure 1**



Sample Acquisi on Order

## Supplemental Figure 2



